Closing

Do GIP/GLP-1 & amylin agonists improve quality of life & behaviour more than other treatments?

Mostly studied in obesity & overweight. Also asked versus placebo.

Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →

Where the evidence stands

Doubtful. So far, the results disagree.

NoUnsureYes
Belief
0.32 (range 0.00–0.55)
Trials for
1
Trials against
2
Inconclusive
4

Already under way

The evidence so far

Registered trials
88
With posted results
16
Published papers
1

Of 67 decided analyses: 22 favor gip/glp-1 & amylin agonists, 24 find no difference, 21 favor the comparator.

Papers

Trials

See every trial in the evidence map →